Novartis reports success in phase 3 trial of drug for rare kidney disease
Novartis reports positive topline results from a Phase 3 trial of iptacopan, a drug to treat a rare kidney disease, C3 glomerulopathy.
Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis reports positive topline results from a Phase 3 trial of iptacopan, a drug to treat a rare kidney disease, C3 glomerulopathy.
Millions of US adults suffering from heartburn associated with non-erosive-gastroesophageal-reflux-disease (GERD) could benefit from an impending treatment by Phathom Pharmaceuticals.
New FDA-approved therapy treatments that use genetic modification called CRISPR may lead to a sickle cell disease cure.
Casgevy, made by two Boston-based pharmaceutical companies, is the first gene therapy based on a technology sometimes called "genetic scissors."
A competing pharmaceutical company is suing SC’s Nephron over drugs it says the company sold without FDA approval, undercutting its own medication on the market.